目的:研究银杏叶提取物(EGB)对肿瘤坏死因子-α(TNF-α)诱导的牛主动脉内皮细胞(BAECs)血凝素样氧化低密度脂蛋白受体-1(LOX-1)表达的影响及其机制。方法:分离培养BAECs,应用TNF-α诱导BAECs表达LOX-1,给予EGB刺激,采用RT-PCR以及W este...目的:研究银杏叶提取物(EGB)对肿瘤坏死因子-α(TNF-α)诱导的牛主动脉内皮细胞(BAECs)血凝素样氧化低密度脂蛋白受体-1(LOX-1)表达的影响及其机制。方法:分离培养BAECs,应用TNF-α诱导BAECs表达LOX-1,给予EGB刺激,采用RT-PCR以及W estern b lotting的方法检测BAECs LOX-1表达的改变,同时用W estern b lotting检测内皮型一氧化氮合酶(eNOS)蛋白表达的变化,检测细胞培养液中亚硝酸盐(NO2-/NO3-)的含量。结果:TNF-α显著上调LOX-1的表达(P<0.05),EGB显著抑制TNF-α诱导的LOX-1的表达(P<0.05),而一氧化氮合酶抑制剂可显著抑制EGB的效应(P<0.05);TNF-α显著下调eNOS的表达(P<0.05),EGB显著促进eNOS蛋白的表达(P<0.05);TNF-α明显降低亚硝酸盐(NO2-/NO3-)的含量(P<0.05),EGB显著抑制TNF-α诱导的亚硝酸盐(NO2-/NO3-)含量的降低(P<0.05)。结论:EGB显著抑制TNF-α诱导的LOX-1的表达,其作用由EGB上调的NO介导。展开更多
目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随...目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随机分组法分成假手术组、模型组、西洛他唑组(n=8)。观察球囊损伤后内膜增生情况并计算内膜、中膜面积比值,检测血清MDA含量,RT-PCR法和免疫组化法分别检测各组球囊损伤后大鼠颈总动脉血管壁组织中LOX-1mRNA和蛋白的表达。结果西洛他唑组内膜/中膜面积比值(IA/MA)、LOX-1mRNA及蛋白表达水平、血清MDA含量显著低于模型组,差异有统计学意义(P<0.05)。结论西洛他唑可显著抑制内膜增生,抑制LOX-1表达及其介导的氧化应激,这可能是西洛他唑抑制内膜增生的机制之一。展开更多
Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized...Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized LDL (Ox-LDL). LOX-1 supports the binding internalization and proteolytic degradation of oxidized LDL, but not of significant amounts of acetylated LDL. LOX-1 is initially synthesized as a 40 kD precursor protein with N-linked high mannose-type carbohydrate, which is further glycosylated and processed into a 48-kD mature form. In vivo, endothelial cells that cover early therosclerotic lesions, intimal macrophages and smooth muscle cells in advanced atherosclerotic plaques express LOX-1. LOX-1 is cleaved at membrane proximal extracellular domain and released from the cell surface. Measurement of soluble LOX-1 in vivo may provide novel diagnostic strategy for the evaluation and prediction of atherosclerosis and vascular diseases.展开更多
文摘目的:研究银杏叶提取物(EGB)对肿瘤坏死因子-α(TNF-α)诱导的牛主动脉内皮细胞(BAECs)血凝素样氧化低密度脂蛋白受体-1(LOX-1)表达的影响及其机制。方法:分离培养BAECs,应用TNF-α诱导BAECs表达LOX-1,给予EGB刺激,采用RT-PCR以及W estern b lotting的方法检测BAECs LOX-1表达的改变,同时用W estern b lotting检测内皮型一氧化氮合酶(eNOS)蛋白表达的变化,检测细胞培养液中亚硝酸盐(NO2-/NO3-)的含量。结果:TNF-α显著上调LOX-1的表达(P<0.05),EGB显著抑制TNF-α诱导的LOX-1的表达(P<0.05),而一氧化氮合酶抑制剂可显著抑制EGB的效应(P<0.05);TNF-α显著下调eNOS的表达(P<0.05),EGB显著促进eNOS蛋白的表达(P<0.05);TNF-α明显降低亚硝酸盐(NO2-/NO3-)的含量(P<0.05),EGB显著抑制TNF-α诱导的亚硝酸盐(NO2-/NO3-)含量的降低(P<0.05)。结论:EGB显著抑制TNF-α诱导的LOX-1的表达,其作用由EGB上调的NO介导。
文摘目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随机分组法分成假手术组、模型组、西洛他唑组(n=8)。观察球囊损伤后内膜增生情况并计算内膜、中膜面积比值,检测血清MDA含量,RT-PCR法和免疫组化法分别检测各组球囊损伤后大鼠颈总动脉血管壁组织中LOX-1mRNA和蛋白的表达。结果西洛他唑组内膜/中膜面积比值(IA/MA)、LOX-1mRNA及蛋白表达水平、血清MDA含量显著低于模型组,差异有统计学意义(P<0.05)。结论西洛他唑可显著抑制内膜增生,抑制LOX-1表达及其介导的氧化应激,这可能是西洛他唑抑制内膜增生的机制之一。
文摘Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized LDL (Ox-LDL). LOX-1 supports the binding internalization and proteolytic degradation of oxidized LDL, but not of significant amounts of acetylated LDL. LOX-1 is initially synthesized as a 40 kD precursor protein with N-linked high mannose-type carbohydrate, which is further glycosylated and processed into a 48-kD mature form. In vivo, endothelial cells that cover early therosclerotic lesions, intimal macrophages and smooth muscle cells in advanced atherosclerotic plaques express LOX-1. LOX-1 is cleaved at membrane proximal extracellular domain and released from the cell surface. Measurement of soluble LOX-1 in vivo may provide novel diagnostic strategy for the evaluation and prediction of atherosclerosis and vascular diseases.
